Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E13.19 EPS (ttm)5.85 Insider Own0.40% Shs Outstand1.30B Perf Week-0.90%
Market Cap100.58B Forward P/E11.72 EPS next Y6.58 Insider Trans-7.08% Shs Float1.29B Perf Month-0.27%
Income7.69B PEG- EPS next Q1.61 Inst Own80.90% Short Float1.12% Perf Quarter15.09%
Sales23.20B P/S4.34 EPS this Y-22.80% Inst Trans0.05% Short Ratio2.18 Perf Half Y-3.71%
Book/sh16.70 P/B4.62 EPS next Y0.18% ROA3.30% Target Price87.87 Perf Year6.59%
Cash/sh19.89 P/C3.88 EPS next 5Y-5.54% ROE10.10% 52W Range64.27 - 89.54 Perf YTD7.72%
Dividend2.28 P/FCF18.04 EPS past 5Y36.20% ROI19.90% 52W High-13.82% Beta1.07
Dividend %2.95% Quick Ratio2.90 Sales past 5Y21.90% Gross Margin80.70% 52W Low20.07% ATR1.42
Employees10000 Current Ratio3.00 Sales Q/Q-20.90% Oper. Margin45.40% RSI (14)53.04 Volatility1.80% 1.80%
OptionableYes Debt/Eq1.34 EPS Q/Q-40.80% Profit Margin9.50% Rel Volume0.69 Prev Close76.73
ShortableYes LT Debt/Eq1.20 EarningsJul 25 AMC Payout128.20% Avg Volume6.61M Price77.17
Recom2.10 SMA20-0.46% SMA503.97% SMA2002.96% Volume4,904,753 Change0.57%
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Aug-14-18 05:11AM  Congo starts using experimental Ebola treatment Reuters
Aug-13-18 12:36PM  Shire, Shionogi File NDA for Intuniv for Adults in Japan Zacks
10:16AM  Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold Zacks
Aug-10-18 01:56PM  Biotech ETFs in Focus on String of Q2 Earnings Beat Zacks
12:30PM  Gilead Sciences Seen Rising 13% on Better Outlook Investopedia
10:48AM  You Better Be Careful with Merck Stock, Especially at These Highs InvestorPlace
09:32AM  Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat Zacks
Aug-09-18 11:48AM  PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y Zacks
10:00AM  Is Crispr Therapeutics Stock Grossly Overvalued? Motley Fool
09:31AM  Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well Zacks
09:17AM  Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise Zacks
Aug-08-18 04:18PM  3 Top Biotech Stocks to Buy in August Motley Fool
03:10PM  Backed with $140M, startup launches three-pronged attack on liver diseases American City Business Journals
10:42AM  Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates Zacks
10:14AM  VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y Zacks
09:17AM  Better Buy: Gilead Sciences, Inc. vs. Amgen Inc. Motley Fool
08:18AM  Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus Zacks
07:52AM  Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges Zacks
Aug-07-18 01:00PM  Why Health Care Stocks Are Outshining The Techs Investopedia
Aug-06-18 04:15PM  Can These Biotech Companies Catch Novartis, Gilead In CAR-T? Investor's Business Daily
03:41PM  Q2 Scorecard & Research Reports for Gilead, American Tower & Others Zacks
11:40AM  Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat Zacks
06:09AM  China National Drug Administration Approves Gileads Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection Business Wire
Aug-03-18 01:25AM  Edited Transcript of GILD earnings conference call or presentation 25-Jul-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-02-18 09:27AM  5 Cheap PEG Stocks Suitable for GARP Investors Zacks
Aug-01-18 09:34AM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit Zacks
Jul-31-18 09:30AM  Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? Zacks
06:33AM  Better Buy: Biogen Inc. vs. Gilead Sciences, Inc. Motley Fool
Jul-30-18 12:09PM  Could Gilead Merge With Pfizer Or Vertex To Solve Its CEO Problem? Investor's Business Daily
11:01AM  Is Gilead Sciences' Sudden Change in Leadership a Good Thing? Motley Fool
08:10AM  Today's Research Reports on Trending Tickers: Progenics Pharmaceuticals and Gilead Sciences ACCESSWIRE
Jul-29-18 06:31AM  3 Cheap Big Pharma Dividend Stocks That You Can Buy Now and Hold for Years Motley Fool
Jul-27-18 03:09PM  2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited Motley Fool
09:00AM  Forget Gilead Sciences' CEO Departure -- This Was the Biotech's Big News Motley Fool
Jul-26-18 01:30PM  Options traders see more upside in Gilead CNBC Videos
01:09PM  Facebook tumbling on revenue hit, AMD popping, Gilead's CEO departs Yahoo Finance
11:43AM  Biotech Earnings: Celgene, Gilead Stocks Head in Opposite Directions Barrons.com
10:53AM  Facebook tumbling on revenue hit, AMD popping, Gilead's CEO departs Yahoo Finance Video
09:54AM  Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day Zacks
08:42AM  Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit Zacks
08:40AM  Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold Benzinga
07:54AM  Stocks making the biggest moves premarket: CMCSA, LUV, FB, QCOM & more CNBC
07:07AM  Nasdaq futures are under pressure as Facebook shares plummet CNBC
06:30AM  CEO Departure at Gilead Sciences Upstages Good Second-Quarter Results Motley Fool
Jul-25-18 08:15PM  [$$] Gilead Sciences CEO Stepping Down The Wall Street Journal
06:53PM  [$$] Gilead Sciences CEO Stepping Down The Wall Street Journal
06:34PM  Gilead CEO Milligan, Chairman Martin to step down Reuters
06:30PM  Gilead President and CEO John Milligan stepping down American City Business Journals
06:09PM  After-hours buzz: FB, F & more CNBC
05:20PM  Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates Zacks
05:01PM  Gilead's Earnings Fail to Impress TheStreet.com
04:15PM  Gilead shares drop as CEO resignation overshadows solid earnings MarketWatch
04:13PM  Gilead CEO John Milligan Stepping Down From Biotech Giant Bloomberg
04:08PM  Gilead: 2Q Earnings Snapshot Associated Press
04:02PM  Gilead Sciences Announces Third Quarter 2018 Dividend Business Wire
04:01PM  Gilead Sciences Announces Second Quarter 2018 Financial Results Business Wire
04:00PM  Gilead Sciences Announces CEO John F. Milligan to Step Down Business Wire
03:00PM  Gilead Sciences, Inc. to Host Earnings Call ACCESSWIRE
01:31PM  Buy These 3 Risky Biotech Stocks TheStreet.com
09:50AM  Gilead Earnings: No More 'Scary' Results? Barrons.com
08:12AM  Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug Zacks
07:55AM  Gilead Sciences Q2 Earnings Preview Benzinga
04:39AM  [$$] Gilead chief executive out after barely two years Financial Times
Jul-24-18 05:19PM  Facebook earnings What you need to know in markets on Wednesday Yahoo Finance
10:56AM  Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings? Zacks
08:37AM  Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK Zacks
08:35AM  Implied Volatility Surging for Gilead Sciences (GILD) Stock Options Zacks
08:00AM  Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States Business Wire
04:30AM  GSK's two-drug HIV treatment proves itself in key tests Reuters
Jul-23-18 06:05PM  Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings? Zacks
03:25PM  Why I Finally Sold my Gilead Sciences Stock Position Motley Fool
11:10AM  Healthcare ETFs to Buy on Solid Q2 Earnings Expectations Zacks
08:01AM  Better Buy: Gilead Sciences, Inc. vs. Celgene Motley Fool
Jul-22-18 10:46AM  3 Key Things to Watch in Gilead Sciences' Q2 Earnings Report Motley Fool
Jul-20-18 02:25PM  Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings? Zacks
06:15AM  3 Top Healthcare Stocks to Buy in July Motley Fool
Jul-19-18 08:53AM  Gilead's Kite will partner with privately-held Gadeta to develop new cancer therapies MarketWatch
08:30AM  Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors Business Wire
Jul-17-18 06:45PM  Cramer's charts suggest big-name biotech stocks Gilead and Celgene have more room to run CNBC
09:25AM  Sure, these corporate workforces make the big bucks, but do they deserve it? American City Business Journals
Jul-16-18 08:02AM  4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit? Motley Fool
Jul-15-18 06:32AM  3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018 Motley Fool
Jul-14-18 07:16AM  3 Biotech Stocks With Big News Coming in NASH Motley Fool
Jul-13-18 04:01PM  Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018 Business Wire
02:00PM  Gilead's Hot Stock May Have Further to Rise Investopedia
Jul-12-18 10:11AM  3 Real Risks That Could Make You Reconsider Buying Celgene Stock InvestorPlace
06:30AM  If You're Thinking About Buying Gilead Sciences Stock, Now's the Time to Do It Motley Fool
Jul-11-18 07:05PM  Top 5 Biotech Stocks for 2018 Investopedia
07:06AM  3 Stocks With Bullish Setups For The Rest Of The Week Benzinga
Jul-10-18 02:38PM  Nasdaq turns negative as tech stocks give up earlier gains Yahoo Finance Video
09:41AM  The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna Zacks
09:22AM  Trade of the Day: Gilead Sciences (GILD) InvestorPlace
Jul-09-18 05:39PM  Portfolio manager Stephanie Link's two new stock picks CNBC Videos
04:30PM  Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy Business Wire
11:42AM  Top Research Reports for Mastercard, Gilead & Goldman Sachs Zacks
06:00AM  4 Biotechs on Verge of Big Breakouts Investopedia
Jul-06-18 05:29PM  Is health care the ultimate hideout trade? CNBC Videos
04:56PM  Health care stocks have even more room to run, technician... CNBC Videos
03:13PM  Why Biotech Stocks Rallied on Biogen's Alzheimer's Test Zacks
12:48PM  7 Stocks That Can Lead The Market Longterm Investopedia
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM